These 3 case studies illustrate the challenges of intensifying treatment in complex T2D patients--and also the options available to individualize that next step.
Cardiovascular outcomes trials of diabetes drugs have led to label expansions and guideline endorsements. Do you recall the studies and the outcomes? Find out, here.
The SGLT-2 inhibitor canagliflozin was FDA-approved on September 30, 2019, to slow progression of diabetic kidney disease and reduce risk of heart failure hospitalization.
Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.
US adults with type 2 diabetes have acheived negligible change in blood glucose levels, blood pressure, LDL-C levels, and smoking status in the past 15 years, according to a new study.
What's your caffeine IQ? Test your knowledge on the latest caffeine research from its effect on cardiovascular disease to liver cancer with this brief quiz.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Help keep patients with diabetes healthy this flu season with a few of these quick reminders on vaccination, medication, comorbidities, and more.
Caffeine moderation moderates cardiovascular risk, caffeine is not what is keeping you up at night, and 4 more recent studies on caffeine intake.
One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.